Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innovent Biologics Inc (OP: IVBXF )

4.568 UNCHANGED
Streaming Delayed Price Updated: 1:59 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Innovent Biologics Inc

< Previous 1 2 Next >
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
Via Talk Markets
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Via Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Beijing’s Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential... 
Via Talk Markets
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale... 
Via Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody... 
Via Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China... 
Via Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... 
Via Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates... 
Via Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a... 
Via Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and... 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
The  
Via Benzinga
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.